netupitant Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
neurokinin NK1 (substance P) receptor antagonist 4898 290297-26-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Ro 67-3189/000
  • netupitant
Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Delayed emesis has been largely associated with the activation of tachykinin family neurokinin 1 (NK-1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.
  • Molecular weight: 578.60
  • Formula: C30H32F6N4O
  • CLOGP: 6.51
  • LIPINSKI: 2
  • HAC: 5
  • HDO: 0
  • TPSA: 39.68
  • ALOGS: -5.31
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 5.54 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.83 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 34.28 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 10, 2014 FDA HELSINN HLTHCARE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000010262 Neurokinin 1 Antagonists
FDA EPC N0000175786 Substance P/Neurokinin-1 Receptor Antagonist
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:55350 neurokinin-1 receptor antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.9 Basic
pKa2 3.35 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Substance-P receptor GPCR ANTAGONIST Ki 9.02 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D05152 KEGG_DRUG
4033795 VUID
N0000191094 NUI
4033795 VANDF
C1700730 UMLSCUI
CHEBI:85155 CHEBI
GAW PDB_CHEM_ID
CHEMBL206253 ChEMBL_ID
DB09048 DRUGBANK_ID
C508854 MESH_SUPPLEMENTAL_RECORD_UI
5742 IUPHAR_LIGAND_ID
8409 INN_ID
7732P08TIR UNII
6451149 PUBCHEM_CID
1552337 RXNORM
30612 MMSL
d08299 MMSL
015714 NDDF
716123009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AKYNZEO HUMAN PRESCRIPTION DRUG LABEL 2 69639-101 CAPSULE 300 mg ORAL NDA 26 sections